<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Eculizumab: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Eculizumab: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Eculizumab: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8836" href="/d/html/8836.html" rel="external">see "Eculizumab: Drug information"</a> and <a class="drug drug_patient" data-topicid="11727" href="/d/html/11727.html" rel="external">see "Eculizumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708724"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious meningococcal infection:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Life-threatening and fatal meningococcal infections have occurred in patients treated with eculizumab. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.</p>
<p style="text-indent:-2em;margin-left:2em;">Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.</p>
<p style="text-indent:-2em;margin-left:2em;">Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of eculizumab, unless the risks of delaying eculizumab therapy outweigh the risk of developing a meningococcal infection.</p>
<p style="text-indent:-2em;margin-left:2em;">Vaccination reduces, but does not eliminate, the risk of meningococcal infections. Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected.</p>
<p style="text-indent:-2em;margin-left:2em;">Eculizumab is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the Soliris REMS, health care providers must enroll in the program. Enrollment in the Soliris REMS program and additional information are available from the manufacturer (1-888-765-4747) or solirisrems.com.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F4426547"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Soliris</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868860"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Soliris</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F13307680"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Monoclonal Antibody</span>;</li>
<li>
<span class="list-set-name">Monoclonal Antibody, Complement Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F13259673"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Patients must receive meningococcal vaccine at least 2 weeks prior to treatment initiation; if the risk of treatment delay outweighs the risk of developing meningococcal infection then administer vaccine as soon as possible. Revaccinate according to current guidelines with consideration of eculizumab therapy duration. To reduce the risk for meningococcal disease, consider antimicrobial prophylaxis with oral antibiotics (penicillin, or macrolides if penicillin-allergic) for the duration of eculizumab therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28704351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28704351'])">Ref</a></span>). Treatment should be administered at the recommended time interval although administration may be varied by ± 2 days. Dosing interval is weight dependent.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1fbfde62-92ad-44b8-a4cb-302a8c890eef">Atypical hemolytic uremic syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atypical hemolytic uremic syndrome (aHUS):</b> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Patient weight:</p>
<p style="text-indent:-2em;margin-left:6em;">5 kg to &lt;10 kg: IV: Induction: 300 mg weekly for 1 dose; Maintenance: 300 mg at week 2, then 300 mg <b>every 3 weeks</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">10 kg to &lt;20 kg: IV: Induction: 600 mg weekly for 1 dose; Maintenance: 300 mg at week 2, then 300 mg every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">20 kg to &lt;30 kg: IV: Induction: 600 mg weekly for 2 doses; Maintenance: 600 mg at week 3, then 600 mg every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">30 kg to &lt;40 kg: IV: Induction: 600 mg weekly for 2 doses; Maintenance: 900 mg at week 3, then 900 mg every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">≥40 kg: Induction: IV: 900 mg weekly for 4 doses; Maintenance: 1,200 mg at week 5, then 1,200 mg every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Supplemental dosing for patients receiving plasmapheresis or plasma exchange: </i></p>
<p style="text-indent:-2em;margin-left:6em;">If most recent dose was 300 mg, administer 300 mg within 60 minutes after each plasmapheresis or plasma exchange.</p>
<p style="text-indent:-2em;margin-left:6em;">If most recent dose was ≥600 mg, administer 600 mg within 60 minutes after each plasmapheresis or plasma exchange.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Supplemental dosing for patients receiving fresh frozen plasma infusion:</i> If most recent dose was ≥300 mg, administer 300 mg within 60 minutes prior to each infusion of fresh frozen plasma.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51107954"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51107955"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F4426649"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8836" href="/d/html/8836.html" rel="external">see "Eculizumab: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Patients must receive meningococcal vaccine at least 2 weeks prior to treatment initiation; revaccinate according to current guidelines. If urgent eculizumab initiation is necessary and &lt;2 weeks after vaccination, provide 2 weeks of antibacterial prophylaxis; in unvaccinated patients, administer meningococcal vaccine as soon as possible and provide 2 weeks of antibacterial prophylaxis. To reduce the risk for meningococcal disease, consider antimicrobial prophylaxis with oral antibiotics (penicillin, or macrolides if penicillin-allergic) for the duration of eculizumab therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28704351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28704351'])">Ref</a></span>). Administer eculizumab at the recommended time interval or within 2 days of the interval.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1fbfde62-92ad-44b8-a4cb-302a8c890eef">Atypical hemolytic uremic syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atypical hemolytic uremic syndrome:</b>
<b>IV:</b> Induction: 900 mg weekly for 4 doses; Maintenance: 1.2 <b>g</b> at week 5, then 1.2 <b>g </b>every 2 weeks thereafter.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Supplemental dosing for patients receiving plasmapheresis or plasma exchange:</i></p>
<p style="text-indent:-2em;margin-left:6em;">If most recent dose was ≥600 mg, administer 600 mg within 60 minutes after each plasmapheresis or plasma exchange.</p>
<p style="text-indent:-2em;margin-left:6em;">If most recent dose was 300 mg, administer 300 mg within 60 minutes after each plasmapheresis or plasma exchange.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Supplemental dosing for patients receiving fresh frozen plasma infusion:</i> If most recent dose was ≥300 mg, administer 300 mg within 60 minutes prior to each infusion of fresh frozen plasma.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3ee1ba14-2e0f-4121-b7f6-da1eed7e8e50">Heart transplant, antibody-mediated rejection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart transplant, antibody-mediated rejection, treatment (off-label use): Note: </b>Optimal regimen has not been established; refer to published and institutional protocols. Administer antibiotic prophylaxis against <i>Neisseria meningitides</i> for the duration of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34402096']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34402096'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 900 mg weekly for up to 8 weeks in combination with other immunosuppression (eg rabbit antithymocyte globulin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34402096']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34402096'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d13a2d9-50ce-4035-a912-3cf3795210f0">Heart transplant, perioperative desensitization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart transplant, perioperative desensitization (off label use): Note: </b>Optimal regimen has not been established; refer to published and institutional protocols. Vaccinate against <i>Neisseria meningitides</i> at least 2 weeks prior to transplant; if unable to vaccinate, administer appropriate prophylactic antibiotics for the duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251691'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>1.2 <b>g</b> on the day of transplant administered immediately prior to reperfusion in combination with rabbit antithymocyte globulin and IV immune globulin; then 900 mg on postoperative days 1, 7, 14, 21 followed by 1.2 <b>g</b> on days 28, 42, 56 and 900 mg on day 60 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36263111','lexi-content-ref-33251691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36263111','lexi-content-ref-33251691'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="296abaeb-ee5d-4919-a82d-703451a3bc9c">Kidney transplant, antibody-mediated rejection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney transplant, antibody-mediated rejection, treatment (adjunctive) (off-label use): Note: </b>Patients should receive prophylactic antibiotics against <i>N. meningitidis </i>while receiving therapy, and then should receive appropriate vaccination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30801549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30801549'])">Ref</a></span>). Optimal regimen has not been established; refer to published and institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1.2 <b>g</b> within 24 hours of the rejection; then 600 mg after each plasmapheresis session followed by 900 mg weekly for 30 days or until clinical goals are met (eg, donor-specific antibody mean fluorescence intensity ≤5,000; stabilization of kidney function) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30801549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30801549'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="04ffb367-b028-40b8-8698-3bd95b446e36">Kidney transplant, perioperative desensitization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney transplant, perioperative desensitization (adjunctive) (off label): Note:</b> Vaccinate against <i>N. meningitidis </i>14 days prior to receiving therapy or administer appropriate antibiotic prophylaxis if vaccination is not possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31012541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31012541'])">Ref</a></span>). Optimal regimen has not been established; refer to published and institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Fixed duration: </i>IV: </b>1.2 <b>g</b> administered 1 hour prior to reperfusion on day 0, then 900 mg on day(s) 1, 7, 14, 21, and 28, then 1.2 <b>g</b> once weekly during weeks 5, 7, and 9 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31012541','lexi-content-ref-30887675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31012541','lexi-content-ref-30887675'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Unspecified duration: </i>IV: </b>1.2 <b>g</b> administered 1 hour prior to reperfusion on day 0, then 600 mg on day 1 and weekly thereafter for 4 weeks; may continue 1.2 <b>g</b> during week 5 and then every 2 weeks until clinical goals are met (eg, reduction in donor-specific antibody levels) based on institutional protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25731800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25731800'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e8f2ebf9-72e6-4f86-bf51-607fad49b48e">Myasthenia gravis, generalized refractory, chronic immunosuppressive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myasthenia gravis, generalized refractory, chronic immunosuppressive therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in patients with anti-acetylcholine receptor antibody positive (AChR+) myasthenia gravis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Induction: 900 mg once weekly for 4 doses; Maintenance: 1.2 <b>g</b> at week 5, then 1.2 <b>g</b> every 2 weeks thereafter.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Supplemental dosing for patients receiving plasmapheresis or plasma exchange:</i></p>
<p style="text-indent:-2em;margin-left:8em;">If most recent dose was ≥600 mg, administer 600 mg within 60 minutes after each plasmapheresis or plasma exchange.</p>
<p style="text-indent:-2em;margin-left:8em;">If most recent dose was 300 mg, administer 300 mg within 60 minutes after each plasmapheresis or plasma exchange.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Supplemental dosing for patients receiving fresh frozen plasma infusion:</i> If most recent dose was ≥300 mg, administer 300 mg within 60 minutes prior to each infusion of fresh frozen plasma.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="533b3d0e-6a18-4264-be77-ae9e03c9578d">Neuromyelitis optica spectrum disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuromyelitis optica spectrum disorder:</b>
<b>IV:</b> Induction: 900 mg weekly for 4 doses; Maintenance: 1.2 <b>g</b> at week 5, then 1.2 <b>g</b> every 2 weeks thereafter.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Supplemental dosing for patients receiving plasmapheresis or plasma exchange:</i></p>
<p style="text-indent:-2em;margin-left:6em;">If most recent dose was ≥600 mg, administer 600 mg within 60 minutes after each plasmapheresis or plasma exchange.</p>
<p style="text-indent:-2em;margin-left:6em;">If most recent dose was 300 mg, administer 300 mg within 60 minutes after each plasmapheresis or plasma exchange.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Supplemental dosing for patients receiving fresh frozen plasma infusion:</i> If most recent dose was ≥300 mg, administer 300 mg within 60 minutes prior to each infusion of fresh frozen plasma.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="baae2201-4105-4717-bf6e-c5c875d26f7c">Paroxysmal nocturnal hemoglobinuria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Paroxysmal nocturnal hemoglobinuria:</b>
<b>IV:</b> Induction: 600 mg weekly for 4 doses; Maintenance: 900 mg at week 5; then 900 mg every 2 weeks thereafter.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991116"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988431"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F4426631"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (adolescents and adults: 17% to 59%; infants and children: 22%), tachycardia (infants and children: 40%; children: 20%), peripheral edema (adolescents and adults: 20% to 29%; adults: 8%), hypotension (adolescents and adults: 12% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (adolescents and adults: 37% to 50%; infants and children: 17%), insomnia (adolescents and adults: 10% to 24%), fatigue (adolescents and adults: 7% to 20%), dizziness (adults: 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (12% to 22%), pruritus (adolescents and adults: 6% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (adolescents and adults: 10% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (16% to 47%), vomiting (10% to 47%), nausea (adolescents and adults: 12% to 40%), abdominal pain (8% to 33%), gastroenteritis (adolescents and adults: 5% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (adolescents and adults: 15% to 35%; infants and children: 17%), urinary tract symptoms (infants and children: 17%), proteinuria (adolescents and adults: 5% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (adolescents and adults: 17% to 35%), neoplasm (adolescents and adults: 6% to 30%), leukopenia (adolescents and adults: 5% to 24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (adolescents and adults: 24%), influenza (adults: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Catheter infection (infants and children: 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (adolescents and adults: 5% to 20%), back pain (adolescents and adults: 5% to 19%), arthralgia (adolescents and adults: 6% to 17%), musculoskeletal pain (adults: 6% to 15%), muscle spasm (5% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye disease (adolescents and adults: 10% to 29%; infants and children: 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal insufficiency (adolescents and adults: 15% to 29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (infants and children: 20% to 60%; adolescents and adults: 12% to 30%), nasopharyngitis (adolescents and adults: 17% to 55%; infants and children: 17%), nasal congestion (infants and children: 40%; children: 20%), upper respiratory tract infection (5% to 40%), rhinitis (infants and children: 22%), bronchitis (adolescents and adults: 9% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (infants and children: 40% to 80%; adolescents and adults: 17% to 25%; adults: 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Severe hypertension (5% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: High fever (infants and children: 9%), paresthesia (adults: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (adults: 5%), cellulitis (adults: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Viral gastroenteritis (infants and children: 9%), constipation (adults: 7% to 9%), decreased appetite (adults: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (adults: 8%), chronic renal failure (adolescents and adults: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (adults: 8% to 10%), lymphocytopenia (adults: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (≤3%; neutralizing: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection (adults: 7% to 8%), meningococcal infection (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain (adults: 7%), myalgia (adults: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (adults: 9%), hordeolum (adults: 7%), cataract (adults: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (adults: 10%), respiratory tract infection (adults: 7%), oropharyngeal pain (6% to 7%), sinusitis (adults: 6% to 7%), flu-like symptoms (adults: 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Aspergillosis, genitourinary infection, septic meningitis, systemic lupus erythematosus</p></div>
<div class="block coi drugH1Div" id="F4426627"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>US labeling:</i> Unresolved serious <i>Neisseria meningitidis</i> infection; patients not currently vaccinated against <i>Neisseria meningitidis</i> (unless risks of treatment delay outweigh risk of developing a meningococcal infection)</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to eculizumab, murine proteins, or any component of the formulation; unresolved <i>Neisseria meningitidis</i> infection; patients not currently vaccinated against <i>Neisseria meningitidis</i> (unless receiving appropriate prophylactic antibiotic treatment until 2 weeks after vaccination)</p></div>
<div class="block war drugH1Div" id="F4426628"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:0em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Serious infections with <i>Neisseria species</i> (other than <i>N. meningitides</i>), including disseminated gonococcal infections, have been reported. In addition to meningitis, the risk of other infections, especially with encapsulated bacteria (eg, <i>Streptococcus pneumoniae, H. influenzae</i>) is increased with eculizumab treatment (because eculizumab blocks terminal complement activation). Aspergillus infections have occurred in immunocompromised and neutropenic patients. Children should receive vaccination for prevention of <i>S. pneumoniae, H. influenzae</i> according to current ACIP guidelines. Use with caution when administering to patients with any systemic infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Infusion reactions, including anaphylaxis or hypersensitivity, may occur; interrupt infusion for severe reaction (eg, cardiovascular instability, respiratory compromise). Continue monitoring for 1 hour after completion of infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Meningococcal infection: <b>[US Boxed Warning]: Meningococcal (<i>Neisseria meningitidis</i>) infections have occurred in patients receiving eculizumab; may be fatal or life-threatening if not detected and treated promptly. Monitor closely for early signs of meningococcal infection; evaluate and treat promptly if suspected. Follow current meningococcal immunization recommendations for patients with complement deficiencies. Vaccination reduces, but does not eliminate, the risk of meningococcal infections. Vaccinate with meningococcal vaccines at least 2 weeks prior to initiation of treatment (unless the risks of delaying eculizumab outweigh the risk of developing meningococcal infection);</b> revaccinate according to current guidelines, considering the eculizumab duration of therapy. If eculizumab must be initiated urgently and less than 2 weeks after vaccination, provide 2 weeks of antibacterial prophylaxis. If urgent treatment is necessary in an unvaccinated patient, administer meningococcal vaccine(s) as soon as possible and provide patients with 2 weeks of antibacterial prophylaxis. Meningococcal infections developed in some patients despite vaccination. Prophylactic antibiotics were administered in clinical studies until at least 2 weeks after vaccination. To reduce the risk for meningococcal disease, consider antimicrobial prophylaxis with oral antibiotics (penicillin, or macrolides if penicillin-allergic) for the duration of eculizumab therapy (McNamara 2017). Discontinue eculizumab during the treatment of serious meningococcal infections. Eculizumab is associated with a ~2,000-fold increased risk of meningococcal disease (compared to the general population risk).</p>
<p style="text-indent:0em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulation: In clinical trials, anticoagulant therapy was continued in patients who were receiving these agents (due to history of or risk for thromboembolism) prior to initiation of eculizumab. The effect of anticoagulant therapy withdrawal is unknown. Treatment with eculizumab should not alter anticoagulation management.</p>
<p style="text-indent:0em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:0em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation in aHUS: Monitor patients for at least 12 weeks after treatment discontinuation for signs/symptoms of thrombotic microangiopathy (TMA) complications. Signs/symptoms of TMA include angina, dyspnea, mental status changes, seizure, or thrombosis; occurrence of two or repeated measurement of any one of the following: Serum creatinine elevation (≥25% from baseline or nadir), serum LDH elevation (≥25% from baseline or nadir), thrombocytopenia (platelet decrease by ≥25% compared to baseline or peak). If TMA complications occur after stopping eculizumab, consider reinitiation of treatment, plasmapheresis, plasma exchange, fresh frozen plasma infusion, and/or appropriate organ-specific measures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation in PNH: Patients with PNH who discontinue eculizumab treatment may be at increased risk for serious hemolysis; monitor closely for at least 8 weeks after treatment discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Patients should be up to date with all immunizations before initiating therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• REMS program: <b>[US Boxed Warning]: Access is restricted through a REMS program. Prescribers must be enrolled in the program; enrollment and additional information is available at 1-888-765-4747 or solirisrems.com.</b> Counsel patients on the risk of meningococcal infection; ensure patients are vaccinated and provide educational materials.</p></div>
<div class="block foc drugH1Div" id="F4426659"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Soliris: 300 mg/30 mL (30 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F4426548"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16324130"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Soliris Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/30 mL (per mL): $260.92</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868861"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Soliris: 300 mg/30 mL (30 mL) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52614239"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV infusion: Allow to reach room temperature prior to administration. In pediatric patients, infuse over 1 to 4 hours; in adults, infuse over 35 minutes. Do not administer as an IV push or bolus. Decrease infusion rate or discontinue for infusion reactions; do not exceed a maximum 2-hour duration of infusion in adults. Monitor for at least 1 hour following completion of infusion (for signs/symptoms of infusion reaction).</p></div>
<div class="block adm drugH1Div" id="F4426653"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Allow to reach room temperature prior to administration. Infuse over 35 minutes in adults and over 1 to 4 hours in pediatric patients; do not administer as an IV push or bolus. Decrease infusion rate or discontinue for infusion reactions; do not exceed a maximum 2-hour duration of infusion in adults. Monitor for at least 1 hour following completion of infusion (for signs/symptoms of infusion reaction).</p>
<p style="text-indent:-2em;margin-left:2em;">Assess vaccination status prior to initiation; patients must receive meningococcal vaccine at least 2 weeks prior to treatment initiation. If eculizumab must be initiated urgently and less than 2 weeks after vaccination, provide 2 weeks of antibacterial prophylaxis; in unvaccinated patients, administer meningococcal vaccine as soon as possible and provide 2 weeks of antibacterial prophylaxis.</p></div>
<div class="block sts drugH1Div" id="F4426639"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Prior to dilution, store intact vials at 2°C to 8°C (36°F to 46°F); do not freeze. Vials may be stored in the original carton at not more than 25°C (77°F) for only a single period up to 3 days. Protect from light; do not shake. Following dilution, store at room temperature or refrigerate; use within 24 hours. If refrigerated, allow admixture to reach room temperature prior to administration (do not use a heat source for warming).</p></div>
<div class="block meg drugH1Div" id="F7874616"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F125166s431lbl.pdf%23page%3D40&amp;token=fjV7%2BD573hoyijmqGAwRKSmB94h6Tz79SHNO1HfOw38h7cbohVJ5aJRqykD%2FoIs9Eo9DXudhw3IqY2rKUEXc9ucfPQWAjU8%2Fg0T8vDtyVWMi9CZZSxMDZ%2F8r%2F0QdkGNn&amp;TOPIC_ID=109480" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125166s431lbl.pdf#page=40</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53570167"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (FDA approved in pediatric patients [age not specified] and adults). <b>Note:</b> Not indicated for the treatment of hemolytic uremic syndrome related to Shiga toxin <i>Escherichia coli </i>(STEC-HUS); treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis (FDA approved in adults); treatment of generalized myasthenia gravis in patients who are antiacetylcholine receptor antibody positive (FDA approved in adults); treatment of neuromyelitis optica spectrum disorder in patient who are anti-aquaporin-4-antibody positive (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F45748323"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Eculizumab may be confused with elotuzumab, emicizumab-kxwh, evolocumab</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299250"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6220068"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F4426623"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Eculizumab crosses the placenta (Duineveld 2019; Eliesen 2021; Gustavsen 2017; Hallstensen 2015; Kelly 2015; Miyasaka 2016).</p>
<p style="text-indent:0em;margin-top:2em;">The Alexion pharmacovigilance database has collected data on 434 pregnancies following in utero exposure to eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH, 335 patients) or atypical hemolytic uremic syndrome (aHUS, 99 patients), 70% of which resulted in a live birth. Among the 260 pregnancies with known outcomes, rates of congenital malformations in liveborn infants and the rates of miscarriage following in utero exposure to eculizumab were similar to those observed in the general population (Socié 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, dose adjustments of eculizumab may be required during pregnancy (Miyasaka 2016; Sarno 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Pregnant patients with PNH and their fetuses have high rates of morbidity and mortality during pregnancy and the postpartum period. Adverse maternal outcomes include bleeding, infections, miscarriages, worsening cytopenias, and thrombotic events; increased fetal death and premature delivery is also reported. Treatment of PNH with eculizumab may increase fetal survival and decrease maternal complications; however, additional study may be needed (Al-Dosari 2021; Kelly 2015; Manning 2022; Miyasaka 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Adverse maternal outcomes observed with aHUS include preeclampsia and preterm delivery; intrauterine growth restriction, low birth weight, and fetal death are also observed. Pregnancy-associated aHUS is rare, and outcome data following maternal use of eculizumab for the treatment of aHUS in pregnant patients are limited. Treatment may improve pregnancy outcomes (Fakhouri 2021; Gupta 2020; Huerta 2018; Rondeau 2022; Servais 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Case reports describing the use of eculizumab in pregnant patients for myasthenia gravis (Vu 2021) and other diseases characterized by complement activation are limited (Burwick 2022; Sarno 2019; Stefanovic 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers are encouraged to enroll patients exposed to eculizumab during pregnancy by contacting the disease specific registry websites (www.pnhregistry.com or www.ahusregistry.com for PNH or aHUS) or by calling 215-616-3558 (for PNH, aHUS, or gMG).</p></div>
<div class="block mopp drugH1Div" id="F53570168"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to therapy: Assess meningococcal vaccination status prior to initiation.</p>
<p style="text-indent:-2em;margin-left:2em;">During therapy: CBC with differential, lactic dehydrogenase (LDH), SCr, AST, urinalysis; early signs/symptoms of meningococcal infection; signs and symptoms of infusion reaction (during infusion and for 1 hour after infusion complete).</p>
<p style="text-indent:-2em;margin-left:2em;">After discontinuation:</p>
<p style="text-indent:-2em;margin-left:4em;">Atypical hemolytic uremic syndrome (aHUS): Signs/symptoms of thrombotic microangiopathy (TMA) complications (monitor for ≥12 weeks after treatment discontinuation), including angina, dyspnea, mental status changes, seizure, or thrombosis; occurrence of 2 or repeated measurement of any one of the following: SCr elevation (≥25% from baseline or nadir), serum LDH elevation (≥25% from baseline or nadir), thrombocytopenia (platelet decrease by ≥25% compared to baseline or peak).</p>
<p style="text-indent:-2em;margin-left:4em;">Paroxysmal nocturnal hemoglobinuria (PNH): Signs and symptoms of intravascular hemolysis (monitor for ≥8 weeks after discontinuation), including anemia, fatigue, pain, dark urine, dyspnea, or thrombosis.</p></div>
<div class="block pha drugH1Div" id="F4426642"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Eculizumab is a humanized monoclonal IgG antibody that binds to complement protein C5, preventing cleavage into C5a and C5b. Blocking the formation of C5b inhibits the subsequent formation of terminal complex C5b-9 or MAC. Terminal complement-mediated intravascular hemolysis is a key clinical feature of paroxysmal nocturnal hemoglobinuria (PNH); blocking the formation of membrane attack complex (MAC) results in stabilization of hemoglobin and a reduction in the need for RBC transfusions. Impairment of complement activity regulation leads to uncontrolled complement activation in atypical hemolytic uremic syndrome (aHUS).</p></div>
<div class="block phk drugH1Div" id="F4426644"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: PNH: Reduced hemolysis: ≤1 week</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 5 to 8 L</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~270 to 414 hours (during plasma exchange the half-life is reduced to 1.26 hours)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038892"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bekemv | Soliris</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Epysqli | Soliris</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Elizaria | Soliris</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Soliris</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-34084110">
<a name="34084110"></a>Al-Dosari YM, Al-Zahrani H, Al-Mohareb F, Hashmi S. Pregnancy with paroxysmal nocturnal hemoglobinuria: a case series with review of the literature. <i>Saudi J Med Med Sci</i>. 2021;9(2):178-189. doi:10.4103/sjmms.sjmms_4_20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/34084110/pubmed" id="34084110" target="_blank">34084110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23884270">
<a name="23884270"></a>Ardissino G, Wally Ossola M, Baffero GM, Rigotti A, Cugno M. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. <i>Obstet Gynecol</i>. 2013;122(2, pt 2):487-489. doi: 10.1097/AOG.0b013e31828e2612.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/23884270/pubmed" id="23884270" target="_blank">23884270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19372253">
<a name="19372253"></a>Brodsky RA, “How I Treat Paroxysmal Nocturnal Hemoglobinuria,” <i>Blood</i>, 2009, 113(26):6522-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/19372253/pubmed" id="19372253" target="_blank">19372253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18055865">
<a name="18055865"></a>Brodsky RA, Young NS, Antonioli E, et al, “Multicenter Phase 3 Study of the Complement Inhibitor Eculizumab for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria,” <i>Blood</i>, 2008, 111(4):1840-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/18055865/pubmed" id="18055865" target="_blank">18055865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35514201">
<a name="35514201"></a>Burwick RM, Dellapiana G, Newman RA, et al. Complement blockade with eculizumab for treatment of severe coronavirus disease 2019 in pregnancy: a case series. <i>Am J Reprod Immunol</i>. 2022;88(2):e13559. doi:10.1111/aji.13559<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/35514201/pubmed" id="35514201" target="_blank">35514201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention, “Prevention and Control of Meningococcal Disease Recommendations of the Advisory Committee on Immunization Practices (ACIP),” <i>MMWR Recomm Rep</i>, 2005, 54(RR-7):1-21. Available at <a href="https://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf%20" target="_blank">http://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21293327">
<a name="21293327"></a>Centers for Disease Control and Prevention (CDC), “Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,” <i>MMWR Recomm Rep</i>, 2011, 60(2):1-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/21293327/pubmed" id="21293327" target="_blank">21293327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21270745">
<a name="21270745"></a>Centers for Disease Control and Prevention (CDC), “Updated Recommendations for Use of Meningococcal Conjugate Vaccines – Advisory Committee on Immunization Practices, 2010,” <i>MMWR Morb Mortal Wkly Rep</i>, 2011, 60(3):72-6. Available at <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/21270745/pubmed" id="21270745" target="_blank">21270745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36263111">
<a name="36263111"></a>Chang DH, Youn JC, Dilibero D, Patel JK, Kobashigawa JA. Heart transplant immunosuppression strategies at Cedars-Sinai Medical Center. <i>Int J Heart Fail</i>. 2020;3(1):15-30. doi:10.36628/ijhf.2020.0034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/36263111/pubmed" id="36263111" target="_blank">36263111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25731800">
<a name="25731800"></a>Cornell LD, Schinstock CA, Gandhi MJ, Kremers WK, Stegall MD. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. <i>Am J Transplant</i>. 2015;15(5):1293-1302. doi:10.1111/ajt.13168<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/25731800/pubmed" id="25731800" target="_blank">25731800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101502">
<a name="28101502"></a>Demir E, Yazici H, Ozluk Y, Kilicaslan I, Turkmen A. Pregnant woman with atypical hemolytic uremic syndrome delivered a healthy newborn under eculizumab treatment. <i>Case Rep Nephrol Dial</i>. 2016;6(3):143-148. doi: 10.1159/000454946.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/28101502/pubmed" id="28101502" target="_blank">28101502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30904074">
<a name="30904074"></a>Duineveld C, Wijnsma KL, Volokhina EB, van den Heuvel LPB, van de Kar NCAJ, Wetzels JFM. Placental passage of eculizumab and complement blockade in a newborn. <i>Kidney Int</i>. 2019;95(4):996. doi:10.1016/j.kint.2019.01.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/30904074/pubmed" id="30904074" target="_blank">30904074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32986871">
<a name="32986871"></a>Eliesen GAM, van Drongelen J, van den Broek PHH, et al. Placental disposition of eculizumab, C5 and C5-eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria. <i>Br J Clin Pharmacol</i>. 2021;87(4):2128-2131. doi:10.1111/bcp.14565<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/32986871/pubmed" id="32986871" target="_blank">32986871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33826112">
<a name="33826112"></a>Fakhouri F, Scully M, Ardissino G, Al-Dakkak I, Miller B, Rondeau E. Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a global aHUS registry analysis. <i>J Nephrol</i>. 2021;34(5):1581-1590. doi:10.1007/s40620-021-01025-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/33826112/pubmed" id="33826112" target="_blank">33826112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31012541">
<a name="31012541"></a>Glotz D, Russ G, Rostaing L, et al; C10-002 Study Group. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. <i>Am J Transplant.</i> 2019;19(10):2865-2875. doi:10.1111/ajt.15397<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/31012541/pubmed" id="31012541" target="_blank">31012541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31809447">
<a name="31809447"></a>Gupta M, Govindappagari S, Burwick RM. Pregnancy-associated atypical hemolytic uremic syndrome: a systematic review. <i>Obstet Gynecol</i>. 2020;135(1):46-58. doi:10.1097/AOG.0000000000003554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/31809447/pubmed" id="31809447" target="_blank">31809447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28296762">
<a name="28296762"></a>Gustavsen A, Skattum L, Bergseth G, et al. Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: A case report. <i>Medicine (Baltimore)</i>. 2017;96(11):e6338. doi: 10.1097/MD.0000000000006338.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/28296762/pubmed" id="28296762" target="_blank">28296762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25468724">
<a name="25468724"></a>Hallstensen RF, Bergseth G, Foss S, et al. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. <i>Immunobiology</i>. 2015;220(4):452-459. doi:10.1016/j.imbio.2014.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/25468724/pubmed" id="25468724" target="_blank">25468724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15985537">
<a name="15985537"></a>Hill A, Hillmen P, Richards SJ, et al, “Sustained Response and Long-Term Safety of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria,” <i>Blood</i>, 2005, 106(7):2559-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/15985537/pubmed" id="15985537" target="_blank">15985537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14762182">
<a name="14762182"></a>Hillmen P, Hall C, Marsh JC, et al, “Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients With Paroxysmal Nocturnal Hemoglobinuria,” <i>N Engl J Med</i>, 2004, 350(6):552-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/14762182/pubmed" id="14762182" target="_blank">14762182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17702897">
<a name="17702897"></a>Hillmen P, Muus P, Duhrsen U, et al, “Effect of Complement Inhibitor Eculizumab on Thromboembolism in Patients With Paroxysmal Nocturnal Hemoglobinuria,” <i>Blood</i>, 2007, 110(12):4123-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/17702897/pubmed" id="17702897" target="_blank">17702897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16990386">
<a name="16990386"></a>Hillmen P, Young NS, Schubert J, et al, “The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria,” <i>N Engl J Med</i>, 2006, 355(12):1233-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/16990386/pubmed" id="16990386" target="_blank">16990386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28911789">
<a name="28911789"></a>Huerta A, Arjona E, Portoles J, et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. <i>Kidney Int</i>. 2018;93(2):450-459. doi: 10.1016/j.kint.2017.06.022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/28911789/pubmed" id="28911789" target="_blank">28911789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33997604">
<a name="33997604"></a>Kearney K, Macdonald P, Hayward C, Muthiah K. The use of eculizumab as a bridge to retransplantation for chronic antibody-mediated rejection in a heart transplant recipient: a case report. <i>Eur Heart J Case Rep</i>. 2021;5(5):ytab180. doi:10.1093/ehjcr/ytab180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/33997604/pubmed" id="33997604" target="_blank">33997604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26352814">
<a name="26352814"></a>Kelly RJ, Höchsmann B, Szer J, et al. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>N Engl J Med</i>. 2015;373(11):1032-1039. doi: 10.1056/NEJMoa1502950.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/26352814/pubmed" id="26352814" target="_blank">26352814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34402096">
<a name="34402096"></a>Kittleson MM, Patel N, Chang DH, Kransdorf EP, Kobashigawa JA, Patel JK. Eculizumab for antibody-mediated rejection in heart transplantation: a case-control study. <i>Clin Transplant</i>. 2021;35(12):e14454. doi:10.1111/ctr.14454<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/34402096/pubmed" id="34402096" target="_blank">34402096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27501352">
<a name="27501352"></a>Kulkarni S, Kirkiles-Smith NC, Deng YH, et al. Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial. <i>Am J Transplant</i>. 2017;17(3):682-691. doi:10.1111/ajt.14001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/27501352/pubmed" id="27501352" target="_blank">27501352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29042454">
<a name="29042454"></a>Lefaucheur C, Viglietti D, Hidalgo LG, et al. Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment. <i>J Am Soc Nephrol.</i> 2018;29(2):620-635. doi:10.1681/ASN.2017050589<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/29042454/pubmed" id="29042454" target="_blank">29042454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23738544">
<a name="23738544"></a>Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. <i>N Engl J Med</i>. 2013;368(23):2169-2181.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/23738544/pubmed" id="23738544" target="_blank">23738544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35444730">
<a name="35444730"></a>Manning JE, Anderson RM, Hill A, Zeidan D, Ciantar E. Pregnancy outcomes in women receiving eculizumab for the management of paroxysmal nocturnal haemoglobinuria. <i>Obstet Med</i>. 2022;15(1):45-49. doi:10.1177/1753495X211019899<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/35444730/pubmed" id="35444730" target="_blank">35444730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30887675">
<a name="30887675"></a>Marks WH, Mamode N, Montgomery RA, et al; C10-001 Study Group. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial. <i>Am J Transplant</i>. 2019;19(10):2876-2888. doi:10.1111/ajt.15364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/30887675/pubmed" id="30887675" target="_blank">30887675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28704351">
<a name="28704351"></a>McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(27):734-737. doi: 10.15585/mmwr.mm6627e1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/28704351/pubmed" id="28704351" target="_blank">28704351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26857155">
<a name="26857155"></a>Miyasaka N, Miura O, Kawaguchi T, et al Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. <i>Int J Hematol</i>. 2016;103(6):703-712. doi: 10.1007/s12185-016-1946-x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/26857155/pubmed" id="26857155" target="_blank">26857155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25121475">
<a name="25121475"></a>Orandi BJ, Zachary AA, Dagher NN, et al. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. <i>Transplantation</i>. 2014;98(8):857-863. doi:10.1097/TP.0000000000000298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/25121475/pubmed" id="25121475" target="_blank">25121475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33251691">
<a name="33251691"></a>Patel JK, Coutance G, Loupy A, et al. Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients. <i>Am J Transplant</i>. 2021;21(7):2479-2488. doi:10.1111/ajt.16420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/33251691/pubmed" id="33251691" target="_blank">33251691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34515154">
<a name="34515154"></a>Rondeau E, Ardissino G, Caby-Tosi MP, et al; Global aHUS registry. Pregnancy in women with atypical hemolytic uremic syndrome. <i>Nephron</i>. 2022;146(1):1-10. doi:10.1159/000518171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/34515154/pubmed" id="34515154" target="_blank">34515154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30159857">
<a name="30159857"></a>Sarno L, Tufano A, Maruotti GM, Martinelli P, Balletta MM, Russo D. Eculizumab in pregnancy: a narrative overview. <i>J Nephrol</i>. 2019;32(1):17-25. doi:10.1007/s40620-018-0517-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/30159857/pubmed" id="30159857" target="_blank">30159857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30412654">
<a name="30412654"></a>Schinstock CA, Bentall AJ, Smith BH, et al. Long-term outcomes of eculizumab-treated positive crossmatch recipients: allograft survival, histologic findings, and natural history of the donor-specific antibodies. <i>Am J Transplant.</i> 2019;19(6):1671-1683. doi:10.1111/ajt.15175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/30412654/pubmed" id="30412654" target="_blank">30412654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27587606">
<a name="27587606"></a>Servais A, Devillard N, Frémeaux-Bacchi V, et al. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. <i>Nephrol Dial Transplant</i>. 2016;31(12):2122-2130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/27587606/pubmed" id="27587606" target="_blank">27587606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30768680">
<a name="30768680"></a>Socié G, Caby-Tosi MP, Marantz JL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. <i>Br J Haematol</i>. 2019;185(2):297-310. doi:10.1111/bjh.15790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/30768680/pubmed" id="30768680" target="_blank">30768680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Soliris.1">
<a name="Soliris.1"></a>Soliris (eculizumab) [prescribing information]. Boston, MA: Alexion Pharmaceuticals Inc; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SolirisCAN.1">
<a name="SolirisCAN.1"></a>Soliris (eculizumab) [Canadian product monograph]. Zurich, Switzerland: Alexion Pharma GmbH; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21942930">
<a name="21942930"></a>Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. <i>Am J Transplant</i>. 2011;11(11):2405-2413. doi:10.1111/j.1600-6143.2011.03757.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/21942930/pubmed" id="21942930" target="_blank">21942930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30909646">
<a name="30909646"></a>Stefanovic V. The extended use of eculizumab in pregnancy and complement activation⁻associated diseases affecting maternal, fetal and neonatal kidneys-the future is now? <i>J Clin Med</i>. 2019;8(3):407. doi:10.3390/jcm8030407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/30909646/pubmed" id="30909646" target="_blank">30909646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801549">
<a name="30801549"></a>Tan EK, Bentall A, Dean PG, Shaheen MF, Stegall MD, Schinstock CA. Use of eculizumab for active antibody-mediated rejection that occurs early post-kidney transplantation: a consecutive series of 15 cases. <i>Transplantation</i>. 2019;103(11):2397-2404. doi:10.1097/TP.0000000000002639<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/30801549/pubmed" id="30801549" target="_blank">30801549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19821824">
<a name="19821824"></a>Taylor CM, Machin S, Wigmore SJ, et al, “Clinical Practice Guidelines for the Management of Atypical Haemolytic Uraemic Syndrome in the United Kingdom,” <i>Br J Haematol</i>, 2010, 148(1):37-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/19821824/pubmed" id="19821824" target="_blank">19821824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37080658">
<a name="37080658"></a>Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2023;42(5):e1-e141. doi:10.1016/j.healun.2022.10.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/37080658/pubmed" id="37080658" target="_blank">37080658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33708096">
<a name="33708096"></a>Vu T, Harvey B, Suresh N, Farias J, Gooch C. Eculizumab during pregnancy in a patient with treatment-refractory myasthenia gravis: a case report. <i>Case Rep Neurol</i>. 2021;13(1):65-72. doi:10.1159/000511957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/33708096/pubmed" id="33708096" target="_blank">33708096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35001433">
<a name="35001433"></a>Yerly P, Rotman S, Regamey J, et al. Complement blockade with eculizumab to treat acute symptomatic humoral rejection after heart transplantation. <i>Xenotransplantation</i>. 2022;29(1):e12726. doi:10.1111/xen.12726<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eculizumab-pediatric-drug-information/abstract-text/35001433/pubmed" id="35001433" target="_blank">35001433</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 109480 Version 138.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
